Drug Profile
CNS disorders therapeutic agent - JCR/Sumitomo Pharma
Latest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Developer JCR Pharmaceuticals; Sumitomo Pharma
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
- Discontinued Mental disorders